Interleukin-2 receptor targeted therapy of ocular disease of HTLV-1-associated adult T-cell leukemia.
OBJECTIVE
To report two cases of patients with ocular manifestations of human T-cell lymphotropic virus type-1 (HTLV-1) associated adult T-cell leukemia/lymphoma (ATL) who were successfully treated with interleukin-2 receptor targeted therapies.


METHODS
Case series.


RESULTS
Two patients with HTLV-1-associated ATL developed symptomatic scleritis. In the first case, conjunctival biopsy showed leukemic infiltration that was confirmed by T-cell receptor polymerase chain reaction (PCR) demonstrating a clonal rearrangement. As treatment for ATL, both cases received interleukin-2 receptor targeted therapy. In one patient, daclizumab, a monoclonal antibody directed against the alpha chain of the interleukin-2 (IL-2) receptor, was used. The second patient was treated with denileukin diftitox, an immunotoxin fusion protein that targets the IL-2 receptor. Improvement in scleritis was noted in both patients.


CONCLUSIONS
Scleritis in patients with underlying HTLV-1-associated ATL is responsive to IL-2 receptor targeted therapies.
Theresa A
TA
Larson
Mengjun
M
Hu
John E
JE
Janik
Robert B
RB
Nussenblatt
John C
JC
Morris
H Nida
HN
Sen
D000293:Adolescent; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D000077561:Daclizumab; D004167:Diphtheria Toxin / Q000627:therapeutic use*; D004317:Doxorubicin / Q000627:therapeutic use; D015828:Eye Infections, Viral / Q000188:drug therapy*; D005260:Female; D015490:HTLV-I Infections / Q000188:drug therapy*; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000627:therapeutic use*; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000188:drug therapy* / Q000821:virology*; D008297:Male; D008875:Middle Aged; D058990:Molecular Targeted Therapy; D011241:Prednisone / Q000627:therapeutic use; D015375:Receptors, Interleukin-2 / Q000037:antagonists & inhibitors*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use; D014792:Visual Acuity / Q000187:drug effects
D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D004167:Diphtheria Toxin; D007074:Immunoglobulin G; D007376:Interleukin-2; D015375:Receptors, Interleukin-2; D011993:Recombinant Fusion Proteins; C078456:denileukin diftitox; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D000077561:Daclizumab; D011241:Prednisone